Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements | ||
By: GlobeNewswire - 26 Feb 2024 | Back to overview list |
|
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). In the Notification Letter, the staff of Nasdaq has determined that for the 10 consecutive business days from February 5, 2024 to February 16, 2024, the closing bid price of the Company’s ordinary shares had been at $1.00 per share or greater. Accordingly, the bid price deficiency matter as previously disclosed is now closed. In addition, on February 20, 2024, the Company received a written notification on periodic filing compliance (the “Letter”) from Nasdaq that it has met the periodic filing requirement for Nasdaq Listing Rule 5250(c)(2) (the “Rule”). In the Letter, the staff of Nasdaq has determined the Company complies with the Rule as the Company filed its Form 6-K for the period ended June 30, 2023 on February 2, 2024. Accordingly, the filing delinquency matter as previously disclosed is now closed. About BeyondSpring Investor Contact: Media Contact: |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |